Aprogen Biologics Inc.
Financials
Valuation Metrics
Aprogen Biologics Inc.'s Market Cap is ₩405B. At end of 2025 it was ₩156B. Ranked #1843 of 2,405 in KR market (top 77%), #703 of 778 on KOSPI (top 90%), #196 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 40.46B KRW | KR#1,843/2,405 Sec#196/231 |
| Revenue | 86.18B KRW | KR#1,501/2,405 Sec#94/231 |
| Net Income | -72.59B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 548.41B KRW | KR#727/2,405 Sec#43/231 |
| Net Assets | 267.71B KRW | KR#782/2,405 Sec#51/231 |
| Employees | 427 | KR#574/2,405 Sec#46/231 |
| Value | ||
| P/B | 0.15x | KR#68/2,405 Sec#3/231 |
| P/S | 0.47x | KR#926/2,405 Sec#41/231 |
| FCF Yield | -118.29% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -27.12% | KR#2,142/2,405 Sec#168/231 |
| ROA | -13.24% | KR#2,154/2,405 Sec#165/231 |
| Op. Margin | -67.00% | KR#2,251/2,405 Sec#164/231 |
| Revenue Growth | 26.13% | KR#429/2,405 Sec#43/231 |
| Financial Health | ||
| Debt Ratio | 104.85% | KR#1,597/2,405 Sec#183/231 |
| Total Debt | 334.33B KRW | KR#382/2,405 Sec#20/231 |
| FCF | -47.86B KRW | KR#2,066/2,405 Sec#205/231 |
| Cash | 22.43B KRW | KR#1,181/2,405 Sec#81/231 |
| Current Ratio | 0.57x | KR#2,090/2,405 Sec#200/231 |
| Dividend | ||
| Div. Yield | 0.00% | KR#1,391/2,405 Sec#87/231 |
| Performance | ||
| 1Y Return | 143.66% | KR#45/2,405 Sec#2/231 |
| 1M Return | -14.00% | KR#1,494/2,405 Sec#153/231 |
| From 52W High | -78.89% | KR#2,271/2,405 Sec#206/231 |
| 1Y MDD | -73.82% | KR#2,106/2,405 Sec#185/231 |
| Trading | ||
| Volume | 47,311 shares | KR#1,003/2,405 Sec#107/231 |
| Trading Value | 63.5M KRW | KR#1,608/2,405 Sec#166/231 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/231 |
| Per Share | ||
| EPS | -2,413 KRW | KR—/2,405 Sec—/231 |
| BPS | 8,900 KRW | KR#1,073/2,405 Sec#74/231 |
Company Info
Aprogen Biologics, founded in 1960, absorbed an affiliate with biopharmaceutical production facilities and technology in 2022, and also incorporated N2TEC, a semiconductor equipment component manufacturer and seller, as a subsidiary. The company's core businesses include pharmaceutical and bio divisions focused on medicine manufacturing and sales, as well as semiconductor equipment component production. Its Osong factory boasts the world's fifth-largest antibody production capacity and collaborates with Aprogen on the production and commercialization of biosimilar medicines. Aprogen Biologics is headquartered in Songpa-gu, Seoul.